Found vs. OrderlyMeds: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, Found is the cheaper program at $289 a month all-in versus OrderlyMeds's $299 — a gap of $10 a month, $120 a year, at the 10 mg maintenance basis. Found: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). OrderlyMeds: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Figure is company-stated; we could not capture it on a pricing page. Prepaid terms reorder things: Found at $169/mo (12-month plan paid up front) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, OrderlyMeds wins at $149 versus $289 all-in — $140/mo apart. Found: Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms). OrderlyMeds: Semaglutide runs $149 a month all-in.

Transparency

Found: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. OrderlyMeds: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Found: none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. OrderlyMeds: none stated; not published.

The gap, compounded over time

Here is what the $10 monthly spread between these two actually buys back over a treatment course — one month, $10; six months, $60; a year, $120; two years of maintenance, $240. Only Found publishes a prepaid tier ($169/mo effective), which undercuts even OrderlyMeds's standing $299 by $1,560/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Maintenance therapies deserve maintenance math: over two years at standing rates, Found bills $6,936 and OrderlyMeds $7,176, a spread of $240 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, Found's $169 effective would total $4,056 — $2,880 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Found holds $289 on every rung (four-month titration: exactly $1,156); OrderlyMeds holds $299 on every rung (four-month titration: exactly $1,196). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $289 at Found versus $299 at OrderlyMeds for the 2.5 mg rung — a wash that the maintenance rates immediately un-wash. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,468/year at Found against $3,588 at the other: $120 of annual daylight for the same molecule and dose. The committed prepayer does best at Found: $169/month effective, $2,028/year, funds up front, refund terms first.

The semaglutide board

The boards split: on semaglutide the order flips, with OrderlyMeds cheaper at $149 against $289 — a reminder that molecule choice can decide the provider question by itself. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Found's ranked figure is $289, with no membership to add; OrderlyMeds's ranked figure is $299, with no membership to add. 2 · Maintenance basis. Found is dose-flat, so its entry and 10 mg figures coincide; OrderlyMeds is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Found: standing $289, prepaid $169 effective (12-month plan paid up front); OrderlyMeds: standing $299, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Found: third-party-reported, read 2026-08-05; OrderlyMeds: no price published, read 2026-08-05. 5 · Pharmacy weighed. Found names no pharmacy; OrderlyMeds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Found: no membership — the medication figure is the billed figure; prepaid 12-month plan paid up front at $169/mo effective; membership recurs; prepaid terms are paid up front; commitment: none month-to-month; prepaid terms for lowest rate. OrderlyMeds: no membership — the medication figure is the billed figure; not published; commitment: none stated. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Found carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. OrderlyMeds carries no price published pricing (last read 2026-08-05), company-stated rather than page-captured; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Found to OrderlyMeds (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Found: shipping included; consultation included; async visit model. OrderlyMeds: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Found if the $10/month tirzepatide saving is the point; you'll prepay for the $169 effective rate; you want the insurance paperwork done for you. Pick OrderlyMeds if the semaglutide line is cheaper here. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are ShedRx at $289 (dose-scaled, no membership); SkinnyRx at $299 (flat, no membership); Amble Health at $300 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,920/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, Found is the cheaper tirzepatide program by $10/mo ; OrderlyMeds's case rests on a cheaper semaglutide line. Both records, with dates and sources, live in the pricing database.